CEO and CFO of Rare Disease Treatment Company Realize Millions in Stock Options

On March 20 and 23, Martin A. Rosblatt, chairman and CEO of rare-disease drug maker United Therapeutics Corp (NASDAQ: UTHR), and CFO James Edgemon exercised stock options and sold the acquired shares in the open market on the same days, each securing roughly $5 million (about 7 billion KRW) in cash.

Rosblatt sold approximately 9,500 shares in two separate transactions, realizing a pre-tax spread of about $3.6 million (roughly 5 billion KRW). Edgemon likewise disposed of around 10,000 shares at similar price levels, generating substantial profits net of the option exercise costs.

Although their direct holdings dipped slightly, Rosblatt still retains over 650,000 shares when including indirect family and trust holdings. The company stated that all sales were pre-arranged under Rule 10b5-1 trading plans established in the second half of 2025.

Meanwhile, United Therapeutics has shown strong momentum since announcing that its inhaled pulmonary arterial hypertension treatment, nebulized Tyvaso, met primary endpoints in the Phase 3 TETON-1 trial for pulmonary fibrosis. On March 30, the stock jumped more than 10%, with trading volume swelling to about $1 billion. And on February 25, the company’s Q4 2025 earnings per share exceeded analyst estimates and its 2026 guidance was upbeat, driving a double-digit share price rise immediately after the results.

Headquartered in Silver Spring, Maryland, United Therapeutics develops and markets therapies for life-threatening rare and serious diseases—such as pulmonary arterial hypertension and pulmonary fibrosis—as well as organ-transplant technologies. Founder and CEO Martin Rosblatt, who previously launched Sirius Satellite Radio, established the company to pursue a treatment for a family member’s rare disease and continues to lead its development of pulmonary therapies, artificial organs, and xenotransplantation technologies.